Skip to main content
CATX
NYSE Life Sciences

Perspective Q3 2026: $202M Cash Into 2028, PSV359 Fast Track, Merck Collaboration

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.86
Mkt Cap
$97.668M
52W Low
$0.781
52W High
$6.16
52W Position info
10% above low
Off High info
86% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

CATX is trading near its 52-week low of $0.781 (10% above the low).

Summary

Perspective ended the third quarter with about $202 million in cash and investments, enough to fund operations into 2028, while reporting a $32.4 million quarterly net loss. The release also disclosed FDA Fast Track status for PSV359 and a Merck supply collaboration for Keytruda combination studies.


Key Events · Earnings and Guidance · CATX

  • Q3 Loss Widens on Higher R&D

    Net loss was $32.4 million, or $0.27 per share, versus $26.0 million, or $0.35 per share, a year earlier; R&D rose to $26.1 million from $20.3 million.

  • Cash Runway Extended Into 2028

    Cash, cash equivalents and short-term investments totaled approximately $202 million at September 30, 2026, up from approximately $145 million at December 31, 2025.

  • PSV359 Wins FDA Fast Track

    In October 2026 the FDA granted Fast Track Designation to PSV359 for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors.

  • Merck Keytruda Supply Agreement

    A September 2026 clinical trial collaboration and supply agreement with Merck supports evaluating PSV359 with Keytruda in certain lung and colorectal cancers.


Analysis · CATX · Life Sciences

Balance sheet durability is the quarter's headline: roughly $202 million in cash and short-term investments at September 30, 2026, which management says funds planned clinical milestones and operations into 2028. That removes near-term financing pressure for a company burning about $34.3 million a quarter in operating expenses, even as the net loss widened to $32.4 million from $26.0 million a year earlier on higher R&D spending. Alongside the numbers, PSV359 picked up FDA Fast Track Designation in October 2026 for FAP-positive solitary fibrous tumors, and a September 2026 clinical collaboration with Merck will supply Keytruda for combination testing in certain lung and colorectal cancers. The lead program, bamzireotide navoxetan, has closed enrollment in Cohort 4 and is targeting an end-of-Phase 2 meeting with the FDA in the first quarter of 2027, the gate to a registrational study.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CATX was trading at $0.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $97.7M. The 52-week trading range was $0.78 to $6.16. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CATX - Latest Insights

CATX
Nov 06, 2026, 12:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.85005
Real-time Price: $0.828259 info
Change: -$0.021791 (-3%) info
Market Cap: $97.668M info
CATX
Nov 06, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8199
Real-time Price: $0.828259 info
Change: +$0.008359 (+1%) info
Market Cap: $97.668M info